Key facts
- Notable investors include Flerie, Signet Healthcare Partners.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for NorthX Biologics Matfors
- ·The full record, as it builds
Funding rounds
No funding rounds for NorthX Biologics Matfors are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NorthX Biologics Matfors
Provider of biologics services intended to provide support to cell and gene therapy projects and products. The company offers support for development processes and analytics, plasmid deoxyribonucleic acid services, protein production analysis, cell banking services, deoxyribonucleic acid sequencing analysis, and more, enabling biotechnology companies to bring medicines to patients efficiently.
- Sector
- Healthcare
- HQ
- Matfors, Sweden
- Founded
- 1963
- Employees
- 120
- Website
- nxbio.com/
- Ownership
- Privately Held (backing)
NorthX Biologics Matfors doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NorthX Biologics Matfors shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NorthX Biologics Matfors in its N-PORT filings yet. We sweep new filings monthly.